Introduction: PRI-002 is an orally available anti-amyloid beta (A ) prionic compound developed for direct disassembly of toxic A oligomers relevant to Alzheimer's disease.
of AD in three different laboratories successfully proved therapeutic efficacy of PRI-002 by improving cognition and decelerating neurodegeneration. Therapeutic efficacy could be shown even under truly nonpreventive treatment conditions, and when applied orally 2,4-6 normalized the cognitive abilities and behavior of transgenic mice up to levels of healthy wild-type littermates. 4 The primary end points were safety and tolerability. The secondary objective was the assessment of pharmacokinetic (PK) characteristics of PRI-002.
For the single ascending dose (or SAD) study, capsules were filled with PRI-002 acetate without any excipients. The study medication was prepared at the required dose for each treatment prior to administration at the hospital pharmacy. The placebo treatment matched the appearance and shape of PRI-002 capsules. Each subject within the cohort received a single dose of PRI-002 capsules or placebo capsules, under fasting conditions. Capsules were administered with 250 mL of tap water. Fluid intake was restricted during 1 hour before and 1 hour after drug administration. Food intake was prohibited for at least 8 hours pre-dose (monitored by glucose testing) and 5 hours postdose followed by standardized meals.
In the multiple ascending dose (or MAD) study, PRI-002 was admin- (glucose testing) and 2 hours post-dose, followed by a standardized meal.
In the SAD first-in-human study, 40 healthy male subjects (19-45 years of age), randomly assigned to the treatment, received one oral dose of study drug in the morning after an overnight fast. Eight healthy subjects were assigned to each of the five sequential dose cohorts (4, 12, 36, 108, or 320 mg PRI-002). For each cohort, the first two subjects (sentinels) were randomized in a 1:1 ratio to receive PRI-002 or placebo, and the remaining six subjects in a ratio of 5:1 to receive PRI-002 or placebo. All participants were admitted to the clinical facility on day 1. Sentinels remained at the clinical site through day 4; all other subjects were kept for 1 day after administration and returned thereafter to the facility once daily for visits. The last follow-up visit was 1 week after study drug administration.
In the MAD study, 24 healthy male subjects (21-43 years of age)
were randomly assigned to the treatment and received the fixed dose daily for 14 or 28 days (cohort 1 and cohort 2, respectively).
The study was open for the participation of female subjects, but probably due to the strict inclusion/exclusion criteria, no female subject was recruited.
The sequential cohorts were exposed to an increased dose of PRI-002 in order to identify the maximal administered multiple dose. The study was planned with an adaptive design in order to be able to reduce the dose in case of severe side effects. The first cohort received 160 mg PRI-002, 50% of the maximal administered single safe dose in the SAD study. In case of severe side effects, the dose for the second cohort would have been reduced to 80 mg. Because no severe side effects occurred in the first cohort, the second cohort was dosed with 320 mg.
For both cohorts, the first four subjects (sentinels) were randomized in a ratio of 2:2 to receive PRI-002 or placebo, and the remaining eight subjects in a ratio of 6:2 to receive PRI-002 or placebo. All participants were admitted to the clinical facility on day 1. Sentinels remained at the clinical site through day 8 and subsequently returned daily for dosing and study procedures to the clinical site until day 14/28 (cohort 1/cohort 2). All other subjects were allowed to leave the facility on day 2 after administration and returned for dosing and study procedures to the clinical site at a fixed morning time for 11/25 days (cohort 1/cohort 2). On day 14/28 (cohort 1/cohort 2), all participants were admitted to the clinical site for another 24 hours for PK sampling. A follow-up was performed on days 16/30, 17/31, and at the end of study visit on day 21/35. 
Participants

Safety assessments
Participants were closely monitored for adverse events (AEs) throughout the studies. Safety assessments including physical examination, vital sign measurements, electrocardiography (ECG) recordings including QTc measurement, and clinical laboratory tests were conducted at specified intervals throughout the studies.
The independent Data and Safety Monitoring Board (DSMB)
assessed the safety and PK data of the sentinels and the entire cohort carefully and approved the continuation of the study.
Pharmacokinetic assessments
During the SAD study, blood samples for plasma PK analysis were collected pre-dose and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 18, 24, 36, 48, and 72 hours post-dose. During the MAD study, blood samples for plasma PK analysis were collected pre-dose and at 0.5, 1, 1.5, 2, 2.5, 4 6, 8, 12, and 24 hours post-dose on day 1 for both cohorts and on day 14 (cohort 1) or day 28 (cohort 2). For the remaining study, the day 1 blood sample was collected pre-dose. After the last administration, additional blood samples were collected at 36, 48, and 72 hours post-dose and on day 21/35 (cohort 1/cohort 2). PRI-002 plasma concentrations were quantified using a validated liquid chromatography method with tandem mass spectrometric detection. The method had been qualified in terms of specificity, reproducibility, precision, and robustness. The lower limit of quantification (LLOQ) had been set to 0.5 ng/mL. PRI-002 levels of <0.5 ng/mL were set to zero for PK calculations. In the SAD study, plasma concentrations for each dose level following single oral doses of PRI-002 were used to calculate the following PK parameters: Area under the plasma concentra- In the MAD study, PRI-002 levels found on day 1 of both cohorts were evaluated exclusively for C max , T max , and AUC 0-24h , but not for half-lives because the dosing interval was too short for a reliable estimation of the half-lives of the terminal disposition phase. Trough levels were inspected visually for the time of constant levels, and mean values were calculated from those levels representing steady-state conditions (C ss ). For cohort 1, this interval was from days 8 to 12 and from days 20 to 28 for cohort 2. Individual mean values were assigned to C ss . PK evaluation at the last study days included C max , T max , AUC 0-24h , C last , In the MAD study in cohort 2 only one sentinel was available and passed the sentinel study plan including study day 7. In addition, one subject dropped out of the study after day 9. No samples were obtained on day 10 or later. Thus, a complete set of data was evaluated for six subjects receiving 320 mg/day of PRI-002.
Statistical analysis
Both phase I studies were conducted with a sufficient number of volunteers to fulfill the study objectives of safety and PK. Descriptive statistics was used to evaluate the data. The PK and statistical analyses of the 
RESULTS
Safety and tolerability results
Safety summary for the SAD study
There were no deaths, serious AEs, severe AEs, or discontinuations because of a treatment-emergent AE reported in the SAD study. A total of six participants (20%) who were given PRI-002 reported non-serious AEs considered probably or possibly related to study treatment, compared with three participants (30%) who received placebo. A summary of these AEs is presented in Table 1 . The severity of eight of these treatment-emergent AEs was deemed mild and included EEG abnormalities only, whereas the severity of one AE (headache) was graded as moderate. No dose-related trend in the incidence of AEs was observed with increasing doses of PRI-002.
Overall, there were no major changes in the course of the blood chemistry and hematology attributable to study treatment. There were no clinically significant alterations in the physical exploration, vital signs, ECG, or EEG during the course of the study. No apparent treatment-or dose-related trends in the 12-lead ECG parameters were noted following any dose of PRI-002 or placebo.
Safety summary for the MAD study
There were no deaths, serious AEs, severe AEs, or discontinuations because of a treatment-emergent AE reported in the MAD study. One subject was withdrawn from the study due to an unrelated serious AE (broken lower jaw due to bicycle accident). A total of one participant (6.7%) given PRI-002 reported non-serious AEs compared with one participant (12.5%) who received placebo. A summary of these AEs is presented in Table 2 .
There were two non-serious AEs assessed by the principal investigator to be possibly related to the study treatment ( 
Pharmacokinetic results
Pharmacokinetic evaluation of the SAD study
Plasma levels of PRI-002 at the two lower doses were below 0.5 ng/mL (LLOQ). At the dose level of 36 mg, levels were close to the determination limit and reliable PK parameters could not be calculated for all subjects. Therefore, no stable means were presentable. Mean PK parameters of PRI-002 are presented in Table 3 and Figure 1 .
Following oral administration of the two higher doses (108 and 320 mg), PRI-002 plasma levels were detectable after 0.25 to 0.5 hours and mean C max levels were 2.92 or 19.6 ng/mL reached at mean T max of 3.08 or 1.17 hours in cohorts 4 and 5, respectively. AUC 0-inf accounted for 39.2 ng*hour/mL (dose 108 mg) or 157 ng*hour/mL (dose 320 mg).
Whereas the ratio of C max was 1:6.8 between both dose groups, the Table 4 shows the mean plasma PK parameters of cohort 1 and cohort 2. Figure 1 shows the mean PRI-002 plasma concentrations at certain time points (full PK profile at day 1 and day 14/28) (A-D) and over the total treatment period (E-F).
Pharmacokinetic evaluation of the MAD study
Mean plasma levels
Mean plasma levels of the cohort 1 show a sharp peak on both full study days, a steady state of pre-treatment levels after about 8 days, and a slow decrease of plasma levels at the end of treatment ( Figure 1E ). The coefficients of variation (CVs) of C max , T max , and AUC 0-24h were 58%, 50%, and 38%, respectively. Mean PK parameters of day 14 showed a similar variation as on day 1, with CVs of 53%, 37%, 64%, and 34% for C max , T max , AUC 0-24h , and C last , respectively. The mean value of t ½ was 4.6 hours, showing a low CV of 20%. The mean t ½ß was 38.5 hours (CV = 34%), which is in agreement with the observation that steady-state conditions were reached after 8 days (corresponding to four to five half-lives). The extrapolated part of the total AUC was 20% on average and thereby met the rule of not being ≥30%.
The accumulation factor at steady state was estimated by the quotient of AUC 0-inf /AUC 0-24h at day 14. The mean accumulation factor was 2.9
for the daily treatment interval.
Mean plasma levels of cohort 2 again show a sharp peak on both full study days, a steady state of pre-treatment levels after about 15 to 20 days, and a slow decrease of plasma levels at the end of treatment ( Figure 1F ). The CVs of C max , T max , and AUC 0-24h were 76%, 54%, and 75%, respectively. Mean PK parameters of day 28 showed a somewhat lower variation compared to day 1, with CVs of 45%, 64%, 28%, and 47% for C max , T max , AUC 0-24h , and C last , respectively. The mean value of t ½ was 3.7 hours, showing a low variance of CV = 25%.
The mean t ½ß was 74.2 hours (CV = 39%), which again is in agreement with the observation that steady-state conditions were reached after 15 days (corresponding to four to five half-lives). The extrapolated part of the total AUC was 21% on average. The accumulation at steady state was 3.0 (using the quotient of C ss (2.76 ng/mL) and C 24h,day1 (0.92 ng/mL) or 3.4 using the quotient of day 28 AUC 0-inf (656 ng*hour/mL)/AUC 0-24h (193 ng*hour/mL) Thus, as in cohort 1, the mean accumulation factor of PRI-002 found in cohort 2 is about three for a daily treatment interval.
When the dose-dependent parameters in both treatment groups were compared, there was a dose-proportional increase from 160 to 320 mg for day 1 and C max , AUC 0-24h , and C ss , with Cohort2/Cohort1- Please note that PK sampling was done only during the first 24 hours and after the last dosing for each cohort. On all other days, only one measurement has been done, pre-dose. The lower limit of quantification (LLOQ) had been set to 0.5 ng/mL. PRI-002 values of <0.5 ng/mL were set to zero for PK calculations Oral clearance rates in humans have been estimated to 2500 to 3500 L/hour, and in the present study mean oral clearance of cohort 5 (SAD study) was calculated to be 566 L/hour.
DISCUSSION
A disease-modifying therapy against AD is of fundamental interest for aging societies, health care systems, as well as for each single current and future AD patient. Because A oligomers are the major neurotoxic agent responsible for disease development and progression [7] [8] [9] [10] [11] and growing evidence suggests that A oligomers, or at least sub-fractions of them, can replicate in a prion-like fashion, [12] [13] [14] anti-A -prionic compounds eliminating toxic A oligomers are a promising new treatment strategy for AD. 1 PRI-002 was designed specifically to eliminate these toxic oligomers and already demonstrated its pre-clinical in vivo efficacy, including in vivo target engagement. 4 In this first-in-human study we could show that single and multiple oral doses of PRI-002 were safe and well tolerated by healthy subjects when administered at single doses ranging from 4 to 320 mg (SAD study) and in the MAD study at daily oral doses of 320 mg for up to 28 days. In both studies (SAD and MAD), AEs were generally mild and balanced between the treatment groups (PRI-002 vs placebo), indicating that they were potentially not drug and dose related. The only serious AE, a broken mandible due to a bicycle accident, was unrelated to the study medication and led to withdrawal of the subject from the study. The metabolic stability of PRI-002 was found to be high in gastric and intestinal simulated fluid as well as in liver microsomes. 16 It is therefore rather unlikely that PRI-002 is rapidly degraded before (gastric or intestinal fluid), during (gut wall) or shortly after absorption (FPE).
Therefore, f has most probably been lowered mainly by incomplete absorption. This is not in contrast to the fact that absorption was rapid and occurred shortly after treatment. Of note, never a second peak or a late T max occurred.
The terminal disposition half-life of 34 hours (cohort 1) or 78 hours (cohort 2) might reflect the relatively high protease-resistance of Damino acid peptides. 16, 17 Due to the limited data of the studies presented here, it is not possible to make a statement regarding the excretion of PRI-002. The present data clearly demonstrate that there is a dose-proportional increase of dose-dependent PK parameters like C max , AUCs, and C ss . It is suggested that the overproportional increase of AUCs in cohort 2 compared to cohort 1 is subject to chance and based on the longer t ½ß of subjects in cohort 2.
When administered daily, the accumulation factor is about 3.
Steady-state plasma levels were reached after about 5 t ½ half-lives.
They increased proportional to dose and reached 2.8 ng/mL (1.8 nM)
at an oral dose of 320 mg PRI-002/day. When compared to plasma levels yielded in successful proof-of-concept studies with transgenic AD mice, plasma levels achieved in humans already after single oral dosing are in the same range of those observed in transgenic mice that received a high therapeutic dose 4 . Therefore, it can be assumed that the necessary plasma levels required for the treatment of AD patients with PRI-002 can be accomplished. The presented data have been obtained in healthy young volunteers and does not allow a sample size calculation of a phase II proof-of-concept trial in AD patients.
In addition, metabolization and blood-brain barrier (BBB) penetration in the AD study population can be different to young volunteers. An allometric scaling should be considered for getting a more precise estimation on the clearance in the intended study population and calculating the dosing for a proof-of-concept trial. In any case, the presented plasma levels of the SAD and MAD studies offer an adequate range for the desired treatment of AD in patients. In conclusion, safety and pharmacokinetic data support further clinical development of PRI-002.
